Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil

Loading...
Loading...
Endo International plcENDP
announced in an
8-K filing
on Wednesday that it plans on terminating its commercial supply and license agreements with
VIVUS, Inc.VVUS
related to its right to commercialize Avanafil. Endo International received exclusive rights to commercialize Avanafil for any urological disease in the US, Canada, and related territories. The company noted that the effective date of the termination will be June 30, 2016. Shares of Vivus were trading lower by 1 percent at $1.00 early Thursday morning.
Posted In: NewsAvanafilEndo Internationalvivus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...